Substituted fused pyrroleimines and pyrazoleimines
US6743817B2 · kind B2 · utility
1Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 6, 2001 |
| Grant date | Jun 1, 2004 |
| Priority date | — |
| Expiry date | Sep 6, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R1 and R2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.